Additional file 1 of Comparative cardiovascular safety of LABA/LAMA FDC versus LABA/ICS FDC in patients with chronic obstructive pulmonary disease: a population-based cohort study with a target trial emulation framework
Creators: name: Chen, Chun-Yu
name: Pan, Sheng-Wei
name: Hsu, Chia-Chen
name: Liu, Jason J.
name: Kumamaru, Hiraku
name: Dong, Yaa-Hui
Publisher: name: figshare
Year: 2023
Subjects: subject: Medicine
subject: Microbiology
subject: FOS: Biological sciences
subject: Pharmacology
subject: Sociology
subject: FOS: Sociology
subject: Immunology
subject: FOS: Clinical medicine
subject: Science Policy

description: Additional file 1: Table S1. Specification and emulation of a target trial of LABA/LAMA FDC versus LABAICS FDC among patients with COPD using real-world data from Taiwan NHIRD. Table S2. International Classification of Diseases, 9th or 10th Revision, Clinical Modification diagnosis codes used to identify patients with COPD. Table S3. Anatomical Therapeutic Chemical classification system codes used to identify use of LABA/LAMA FDC or LABA/ICS FDC. Table S4. International Classification of Diseases, 9th or 10th Revision, Clinical Modification diagnosis codes used to identify outcomes of interest and the positive control outcome. Table S5. International Classification of Diseases, 9th or 10th Revision, Clinical Modification diagnosis or procedure codes or Taiwan health insurance service claims codes used to identify comorbidities and measures of healthcare services at baseline. Table S6. Anatomical Therapeutic Chemical classification system codes used to identify medication use at baseline. Table S7. Measurement of the 11 clinical parameters at baseline. Table S8. Summary of subgroup analyses. Table S9. Patient characteristics of the eligible cohort before and after PS matching. Table S10. Number of patients and events, follow-up duration, incidence rate, and risk of pneumonia comparing LABA/LAMA FDC with LABA/ICS FDC before and after PS matching. Table S11. Number of patients and events, follow-up duration, incidence rate, and risk of composite cardiovascular events comparing LABA/LAMA FDC with LABA/ICS FDC before and after PS matching, by intention-to-treat approach. Table S12. Availability of the clinical parameters at baseline in the eligible cohort. Table S13. Clinical parameters of the imputed cohort before and after PS matching. Table S14. Number of patients, number of events, and risk of composite cardiovascular events comparing LABA/LAMA FDC versus LABA/ICS FDC before and after PS matching, by patient characteristic. Table S15. Number of patients, number of events, and risk of composite cardiovascular events comparing LABA/LAMA FDC versus LABA/ICS FDC before and after PS score matching, by individual LABA/LAMA FDC and LABA/ICS FDC. Table S16. Number of patients, number of events, and risk of composite cardiovascular events comparing LABA/LAMA FDC versus LABA/ICS FDC before and after PS matching, by treatment duration. Table S17. Selected patient characteristics at baseline and cardiovascular outcomes during follow-up of three substantial efficacy trials and our study. Figure S1. Study cohort assembly. Figure S2. Distributions of propensity score by study drug before and after PS matching. Figure S3. Cumulative incidence plots of composite cardiovascular events by study FDC treatment before and after PS matching derived from complement of the Kaplan-Meier survival function. Figure S4. Cumulative incidence plots of composite cardiovascular events by study FDC treatment before and after PS matching accounting for the influence of competing risk from overall death.